Drug Trial Radar · NCT03821935
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
364
Actual
Start
Feb 21, 2019
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jan 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.
Conditions
- Advanced Solid Tumors Cancer
Interventions
LivmoniplimabDrug
Liquid for intravenous infusion.
BudigalimabDrug
Lyophilized powder for solution for intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Recommended Phase 2 Dose (RP2D) Livmoniplimab MonotherapyTime frame: Up to 28 days after the first dose of Livmoniplimab monotherapy
- Dose Escalation: RP2D Livmoniplimab + Budigalimab Combination TherapyTime frame: Up to 28 days after the first dose of Livmoniplimab and Budigalimab combination therapy
- Dose Expansion: Objective Response Rate (ORR)Time frame: Up to approximately 6 months after the first dose date of last participant in Dose Expansion
Locations
64 sites in 14 countries. Site status is shown where the registry gives one.
Highlands Oncology Group, PA /ID# 218942
Springdale, Arkansas
City of Hope National Medical Center /ID# 265620
Duarte, California
City of Hope Orange County Lennar Foundation Cancer Center /ID# 270785
Irvine, California
Yale University School of Medicine /ID# 208356
New Haven, Connecticut
AdventHealth Celebration /ID# 224860
Celebration, Florida
Duplicate_AdventHealth Cancer Institute - Orlando /ID# 226953
Orlando, Florida
Indiana Univ School Medicine /ID# 208384
Indianapolis, Indiana
Community Health Network, Inc. /ID# 257032
Indianapolis, Indiana
Univ Michigan Med Ctr /ID# 221129
Ann Arbor, Michigan
Washington University-School of Medicine /ID# 259684
St Louis, Missouri
Intermountain Health West End Clinic Gynecologic Oncology /ID# 266171
Billings, Montana
NYU Langone Medical Center /ID# 209822
New York, New York
Icahn School of Medicine at Mount Sinai /ID# 264653
New York, New York
Carolina BioOncology Institute /ID# 208358
Huntersville, North Carolina
The Ohio State University - The James /ID# 217611
Columbus, Ohio
Ou Health - Stephenson Cancer Center /ID# 268826
Oklahoma City, Oklahoma
Sarah Cannon Research Institute (SMO/Network/Consortium) /ID# 264900
Nashville, Tennessee
Renovatio clinical /ID# 265109
El Paso, Texas
NEXT Oncology /ID# 208930
San Antonio, Texas
Renovatio Clinical /ID# 265054
The Woodlands, Texas
University of Washington Medical Center /ID# 268854
Seattle, Washington
Chris O'Brien Lifehouse /ID# 213236
Camperdown, New South Wales, Australia
Icon Cancer Centre /ID# 224961
South Brisbane, Queensland, Australia
Cliniques Universitaires UCL Saint-Luc /ID# 218466
Brussels, Brussels Capital, Belgium
University Health Network_Princess Margaret Cancer Centre /ID# 209423
Toronto, Ontario, Canada
Centre Jean Perrin /ID# 218669
Clermont-Ferrand, France
CHU Toulouse - Hopital Purpan /ID# 218667
Toulouse, Haute-Garonne, France
Centre Leon Berard /ID# 218515
Lyon, Rhone, France
Institut Gustave Roussy /ID# 218668
Villejuif, Val-de-Marne, France
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung /ID# 269587
Essen, North Rhine-Westphalia, Germany
Hadassah Medical Center-Hebrew University /ID# 257918
Jerusalem, Israel
Rabin Medical Center /ID# 258479
Petah Tikva, Israel
Rambam Health Care Campus /ID# 222198
Haifa, H_efa, Israel
The Chaim Sheba Medical Center /ID# 209037
Ramat Gan, Tel Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 222199
Tel Aviv, Tel Aviv, Israel
Istituto Europeo Di Oncologia /Id# 266053
Milan, Milano, Italy
National Cancer Center Hospital East /ID# 224808
Kashiwa-shi, Chiba, Japan
Hyogo Cancer Center /ID# 272553
Akashi-shi, Hyōgo, Japan
National Cancer Center Hospital /ID# 209421
Chuo-ku, Tokyo, Japan
Jagiellonskie Centrum Innowacji Sp. z o.o. /ID# 266194
Krakow, Lesser Poland Voivodeship, Poland
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.